Combining radiotherapy with sunitinib: lessons (to be) learned

To improve the efficacy of radiotherapy (RTx), there is a growing interest in combining RTx with drugs that inhibit angiogenesis, i.e., the process of neo-vessel formation out of preexisting capillaries. A frequently used drug to inhibit angiogenesis is sunitinib (Sutent, SU11248), a receptor tyrosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleibeuker, Esther A., ten Hooven, Matthijs A., Verheul, Henk M., Slotman, Ben J., Thijssen, Victor L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2015
Materias:
Review Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596900/
https://www.ncbi.nlm.nih.gov/pubmed/26202788
http://dx.doi.org/10.1007/s10456-015-9476-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596900/
https://www.ncbi.nlm.nih.gov/pubmed/26202788
http://dx.doi.org/10.1007/s10456-015-9476-3

Ejemplares similares